Auvelity's FDA expansion into Alzheimer's agitation—peak sales now projected at $8B—exposes how long antipsychotics dominated a space where safer...
FDA flagged BeOne's Brukinsa TV ad 'Clarity' for misleading visuals—BeOne's third OPDP enforcement letter in under 18 months. Here's...
ZUSDURI demonstrates 64.5% disease-free rate at 36 months in bladder cancer trial, offering durability without maintenance therapy for recurrent...
Upstream Bio caps COPD Study enrollment at 400 participants and pivots to Phase 3 design around quarterly dosing for...
Voyager's VY1706 achieves 64% tau reduction in primates with no safety issues, clearing preclinical path for human trials later...
Oruka's ORKA-001 achieves 63.5% PASI 100 rate at Week 16 in psoriasis, exceeding typical IL-23 inhibitor performance at midpoint...
Avalo's abdakibart achieves 42.5% HiSCR75 response in hidradenitis suppurativa trial, the highest absolute improvement reported in comparable Phase 2...
Oral semaglutide achieves 21.6% weight loss in early responders and nearly doubles mobility gains versus placebo in OASIS 4...
ICON opens early-phase units in San Antonio, Houston, and Lawrence, KS—but sponsors activating satellite clinics face IRB, contract, and...
Zentalis's azenosertib strategy depends on DENALI Phase 2 data readout expected before year-end 2026 in Cyclin E1-positive ovarian cancer...
